David R. Bauer

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 2,481,781 shares of common stock for an aggregate price to the public of approximately $90 million. The…

Davis Polk advised the underwriters in connection with the $34.5 million public offering of 13,800,000 common shares of Affimed N.V. The offering included 1,800,000 common shares sold…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…

Davis Polk advised Intsights Cyber Intelligence Ltd on its $30 million funding round led by Qumra Capital. Launched in 2015 and headquartered in New York, Intsights is trusted by…

Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on…

Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…

Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…